Do My Symptoms Mean Adenomyosis or Endometriosis?

If you’ve been living with debilitating cramps, pelvic pain, pain with sex, heavy bleeding, or infertility, you’ve probably tried to figure out “how likely” adenomyosis or endometriosis is. Maybe you’ve even been dismissed with some version of: “It’s not that common.”

Here’s the problem: prevalence (“how common it is”) depends hugely on who you’re measuring and how you’re diagnosing it. If you look at the general population, the numbers can seem low. If you look at people with the exact symptoms you’re dealing with, the numbers jump dramatically. Recent evidence helps put that into perspective—and can give you stronger language to advocate for evaluation and treatment.

The numbers that matter most aren’t “global”

When people quote big, global prevalence numbers—about 1-2% for adenomyosis and 5-10% for endometriosis—it can sound like these conditions are rare. But those estimates come from “general population” data, which often includes many people who were never evaluated with sensitive tools, never had imaging, never had surgery, or never had symptoms that led to investigation.

For you as a patient, a more relevant question is: “Given my symptoms (or infertility), how often do these diagnoses show up in people like me?”

When researchers looked at groups that match real-life clinical scenarios—people showing up with symptoms or fertility struggles—the prevalence was much higher:

• In people experiencing infertility/subfertility, adenomyosis showed up in about 31% and endometriosis in about 38% (pooled estimates across many studies).
• In people with gynecologic symptoms, adenomyosis prevalence estimates were often around 41%–49% across symptom groups like abnormal uterine bleeding (AUB), pelvic pain, painful sex, and painful periods.
• In symptomatic groups, endometriosis estimates ranged roughly 18%–42%, with higher rates reported in groups defined by pain symptoms like dysmenorrhea and pelvic pain.

You can take one practical message from this: if you have classic symptoms, you are not “unlikely” to have adenomyosis or endometriosis just because a global statistic looks small.

If you have infertility, your odds are not “1–5%”

If you’re trying to conceive and you’ve been relatively dismissed, these prevalence ranges give you a concrete counterpoint. In infertility/subfertility populations, both conditions are common—on the order of about one in three for adenomyosis and more than one in three for endometriosis in pooled estimates.

That doesn’t mean these conditions are the only explanation for infertility. It does mean your care should reflect the reality that they are frequent contributors or co-conditions in fertility clinics and infertility workups—especially when infertility overlaps with pain, heavy bleeding, bowel/bladder symptoms around your period, or a history of ovarian cysts/endometriomas.

Why diagnosis method changes the “how common is it” answer

One of the most important (and validating) points is this: prevalence estimates vary dramatically depending on the diagnostic pathway.

For endometriosis, estimates based on laparoscopy were far higher than estimates based on self-report (about 31% vs 4% in subgroup estimates). That gap doesn’t mean everyone who self-reports is wrong. It means that self-report captures a different group (often those who were told they “probably have it” or never had access to surgery), and surgery tends to occur in people with more severe symptoms or stronger suspicion.

For adenomyosis, prevalence differed depending on whether diagnosis came from histopathology after a hysterectomy has already been performed, MRI, or ultrasound (with subgroup estimates in the low-to-mid 30% range). Translation: imaging choices and the radiologist’s experience can affect whether adenomyosis is seen and reported, and adenomyosis can still be missed—especially if the imaging protocol isn’t optimized or the report isn’t specific.

What this means for you in real life:

• A low number based on self-report or incomplete evaluation can underestimate how often these conditions are actually present in symptomatic people.
• Different clinics can give you different “likelihood” estimates simply because they use different diagnostic tools and thresholds.

Symptom-based prevalence is a permission slip to push for answers

If you have symptoms like:

• severe period pain (dysmenorrhea)
• chronic pelvic pain
• heavy/prolonged bleeding (AUB)
• pain with sex (dyspareunia)
• infertility/subfertility

…then these pooled prevalence ranges support something many patients already know in their bodies: these symptoms are not “normal,” and they deserve a serious evaluation for conditions that commonly cause them.

This is especially important because adenomyosis and endometriosis can coexist, and rather often. These symptom patterns overlap. You might also have one without the other. Your goal isn’t to win a label—it’s to get a treatment plan that targets what’s driving your pain, bleeding, fatigue, and fertility challenges.

What to do with this information at your next appointment

You don’t need to quote a dozen percentages. You need a clear ask: “Given my symptoms, I want an evaluation plan that reflects how common these diagnoses are in symptomatic patients like me.”

Use one of these approaches (pick what fits your situation):

• “My symptoms match groups where adenomyosis can be present in roughly 40–50% of patients. What is our concrete plan to evaluate and treat this?”
• “In infertility populations, adenomyosis and endometriosis are both common. Can we assess for both—and discuss how each might affect my fertility plan?”
• “If ultrasound is negative, what is the next step? Would MRI with an experienced reader change management?”
• “If we suspect endometriosis, are you offering symptom control only, or are we discussing referral to an endometriosis-excision specialist if I’m not improving?”

A realistic timeline: when “watch and wait” is not appropriate

Some clinicians default to “try NSAIDs and birth control and see.” That may be reasonable for mild symptoms—if you’re improving. But persistent symptoms with significant life impact deserve a plan with checkpoints. Keep in mind that medical treatment does not generally eradicate disease, so if your goal is just to reduce symptoms for some period of time that is fine. But you are also kicking the can down the road because medical therapies generally fail at some point and the cycle of active endo converting to fibrosis rolls on all of that time.

A patient-centered way to structure this is:

• set a symptom goal (for example, “pain reduced enough to work/function most days” or “bleeding manageable without anemia”)
• agree on a timeframe to reassess (often 8–12 weeks for a medication trial, sooner if side effects are intolerable)
• define what happens next if you’re not improving (different hormonal approach, pelvic floor therapy if indicated, MRI, referral, surgical consult, infertility evaluation)

Prevalence data doesn’t diagnose you—but it does support that delaying evaluation for years is not benign when you have classic symptoms.

Reality check: why no single percentage can predict your case

It’s tempting to turn prevalence into a personal probability (“I have a 49% chance”). That is basically false precision because that may be the average for your symptoms and not your specific risk.

These pooled estimates had very high variability between studies (the kind of heterogeneity that tells you the studies weren’t all measuring the same thing in the same way). Differences in who got evaluated, symptom severity, country/healthcare access, imaging protocols, surgeon skill, and definitions of disease all change the numbers.

So treat these percentages as:

• benchmarks that validate your symptoms and justify evaluation
• not a definitive prediction of what you personally have

Your symptoms, exam, imaging quality, response to treatments, and fertility goals should drive next steps more than any single statistic.

Practical takeaways you can act on this month

If you’re stuck or being minimized, focus on shifting the conversation from “how common is it” to “what’s our plan.” Bring your symptom history (timing with cycle, bleeding volume, pain triggers, bowel/bladder symptoms, missed work/school days) and ask for a stepwise approach that matches your goals—pain relief, bleeding control, fertility, or all three.

Questions to ask your clinician:

• What diagnoses best explain my symptom pattern (pain + bleeding + bowel/bladder symptoms + infertility)?
• If my ultrasound is normal, what is our next diagnostic step (repeat imaging with an expert, MRI, referral)?
• How will we decide whether medical management is “working enough,” and what’s next if it isn’t?
• If endometriosis is suspected, what are the pros/cons of continuing medical therapy vs referral for surgical evaluation with an excision-trained specialist?
• If I’m trying to conceive, how might suspected adenomyosis/endometriosis change our fertility timeline and treatment plan?

You’re not asking for “extra.” You’re asking for care that matches the reality that these conditions are common in symptomatic and infertility populations—and that your suffering deserves a serious response. Failing that, second opinion with an endometriosis & adenomyosis specialist is prudent to consider.